Page 86 - 2021_12-Haematologica-web

S. Kayser et al.
10. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21 (24):4642-4649.
11. Mitelman F: ISCN: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger; 1995.
12. Yokota S, Kiyoi H, Nakao M, et al. Internal tandem duplication of the FLT3 gene is pref- erentially seen in acute myeloid leukemia and myelodysplastic syndrome among vari- ous hematological malignancies. A study on a large series of patients and cell lines. Leukemia. 1997;11(10):1605-1609.
13. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: associa- tion with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326-4335.
14. Schemper M, Smith TL. A note on quantify- ing follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343-346.
15. Kaplan E, Meier P. Nonparametric estima- tion from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
16. Gray RJ. A class of k-sample tests for com- paring the cumulative incidence of a com- peting risk. Ann Stat. 1988;16(3):1141-1154.
17. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria, 2014.
18.Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133(15):1630- 1643.
19. Jillella AP, Kota VK. The global problem of early deaths in acute promyelocytic leukemia: a strategy to decrease induction mortality in the most curable leukemia. Blood Rev. 2018;32(2):89-95.
20.Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA- 2000 trial of the GIMEMA group. Blood. 2010;116(17):3171-3179.
21. de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all- trans retinoic acid and idarubicin. Blood. 2008;11(7):3395-4302.
22.Testa U, Lo-Coco F. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients. Ann Hematol. 2016;95(5):673-680.
23. Davison K, Mann KK, Miller WH Jr, Davison K. Arsenic trioxide: mechanisms of action. Semin Hematol. 2002;39(2 Suppl 1):3-7.
24. Lo-Coco F, Hasan SK. Understanding the molecular pathogenesis of acute promyelo- cytic leukemia. Best Pract Res Clin Haematol. 2014;27(1):3-9.
25. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall sur- vival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116 (19):3751-3757.
26. Montesinos P, González JD, González J, et al. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic acid and anthracycline-based chemotherapy. J Clin Oncol. 2010;28(24):3872-3879.
27. Pagano L, Pulsoni A. Second malignancy after treatment of acute promyelocytic leukemia: experience of GIMEMA trials. Blood. 2002;100(4):1514-1515.
28. Zhang Y, Zhang Z, Li J, et al. Long-term effi- cacy and safety of arsenic trioxide for first- line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer. 2013;119(1):115-125.
29. Kayser S, Rahmé R, Martínez-Cuadrón D, et al. Outcome of older (70 years) APL patients frontline treated with or without arsenic tri- oxide-an International Collaborative Study. Leukemia. 2020;34(9):2333-2341.
30. Ghavamzadeh A, Alimoghaddam K, Rostami S, et al. Phase II study of single- agent arsenic trioxide for the front-line ther- apy of acute promyelocytic leukemia. J Clin Oncol. 2011;29(20):2753-2757.
31. Kayser S, Schlenk RF, Platzbecker U. Management of patients with acute promyelocytic leukemia. Leukemia. 2018;32 (6):1277-1294.
32. Kiguchi T, Yoshino Y, Yuan B, et al. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia. Leuk Res. 2010;34 (3):403-405.
33. Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009;106(9):3342-3347.
34. Zhu H, Hu J, Chen L, et al. The 12-year fol- low-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia. Blood. 2016;128(11):1525-1528.
acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy. Leuk Res. 2013;37(11):1451-1456.
37.Noguera NI, Catalano G, Banella C, et al. Acute promyelocytic leukemia: update on the mechanisms of leukemogenesis, resist- ance and on innovative treatment strategies. Cancers. 2019;18;11(10):1591.
38. Kiyoi H, Naoe T, Yokota S, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 1997;11(9):1447-1452.
39. Noguera NI, Breccia M, Divona M, et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia. 2002;16 (11):2185-2189.
40. Shih LY, Kuo MC, Liang DC, et al. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. Cancer. 2003;98(6):1206-1216.
41. Lucena-Araujo AR, Kim HT, Jacomo RH, et al. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracy- cline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. Ann Hematol. 2014;93(12): 2001-2010.
42. De Botton S, Chevret S, Sanz M, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor progno- sis: results of APL 93 trial. Br J Haematol. 2000;111(3):801-806.
43. Cervera J, Montesinos P, Hernández-Rivas JM, et al. Additional chromosome abnor- malities in patients with acute promyelocyt- ic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica. 2010;95(3):424-431.
35.
36.
Schlenk RF, Germing U, Hartmann F, et al. High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelo- cytic leukemia. Leukemia. 2005;19(6):978- 983.
Lou Y, Suo S, Tong H, et al. Characteristics and prognosis analysis of additional chro- mosome abnormalities in newly diagnosed
45.Poiré X, Moser BK, Gallagher RE, et al. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma. 2014;55(7):1523-1532.
44.
Pantic M, Novak A, Marisavljevic D, et al. Additional chromosome aberrations in acute promyelocytic leukemia: characteris- tics and prognostic influence. Med Oncol. 2000;17(4):307-313.
46.
Cicconi L, Divona M, Ciardi C, et al. PML- RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemothera- py. Leukemia. 2016;30(10):1987-1992.
3106
haematologica | 2021; 106(12)